Tech Company Financing Transactions
Sana Biotechnology Funding Round
Sana Biotechnology, operating out of Seattle, secured $700 million from Alaska Permanent Fund, Altitude Life Science Ventures and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
6/29/2020
Transaction Type
Venture Equity
Amount
$700,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from Sana's financing will be used to advance discovery and development within the company's core platforms, including gene delivery, immunology, stem cell biology, and gene modification and control.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
188 East Blaine St. 400
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Overview
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Harr
Chief Financial Officer
Nate Hardy
Chief Technical Officer
Ed Rebar
VP - Bus. Development
Christian Hordo
VP - General Counsel
James MacDonald
VP - Operations
Shanna Peek
VP - Product Management
Robin Andrulevich
VP - R & D
Sunil Agarwal
Browse more venture capital transactions:
Prev: 6/29/2020: Arena venture capital transaction
Next: 6/29/2020: GroupSolver venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs